Karyopharm Therapeutics (KPTI)
(Delayed Data from NSDQ)
$0.81 USD
-0.02 (-2.93%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $0.80 -0.01 (-0.99%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth B Momentum F VGM
Brokerage Reports
0 items in cart
Karyopharm Therapeutics Inc. [KPTI]
Reports for Purchase
Showing records 201 - 220 ( 389 total )
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
XPOVIO Sales Beat, We See Shares as Fully Valued, Downgrade to Neutral
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Management Provides 4Q19 Estimated Sales; Raising PT by $1 to $37
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended January 3 2020
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
ASH 2019: Hangover: Covered Companies Roundup
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
ASH 2019: Key Presentations Roundup for Covered Companies Days 1-2
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
3Q19 Financials; Encouraging Start for XPOVIO Launch, Eyes Ahead to BOSTON
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
3Q19 Earnings; Xpovio Launch Starts Strong; Raising PT to $36 From $32
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Royalty Agreement Alleviates Financing Risk, Raising PT
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Xpovio Presentations at the 17th International Myeloma Workshop
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Karyopharm Enters Into Royalty Agreement for up to $150 Million, Cash Runway Now Into Mid-2021
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E